Dodo Mihary, Ratrimoharilala Faniry Notahiantsoa, Ramilitiana Benja, Razafindrakoto Catherine, Rakotoarisoa Nomenjanahary Andriniaina, Randriamanantsoa Lova Narindra, Randriamarotia Harilalaina Willy Franck
Department of Internal Medicine, Analakininina University Hospital, Toamasina, Madagascar.
Nephrology Intensive Care Unit, Joseph Raseta Andrianavalona University Hospital, Madagascar.
Tunis Med. 2024 Aug 5;102(8):472-477. doi: 10.62438/tunismed.v102i8.4830.
Urinary tract infection is the leading cause of nosocomial infection worldwide. It is a factor in the progression of chronic kidney disease.
To determine the epidemiological, clinical, microbiological, therapeutic and evolving profile of patients with chronic kidney disease and urinary tract infection.
This was a retrospective, descriptive study lasting 5 years, from January 2014 to december 2018 in chronic kidney disease with urinary tract infection.
Fifty-one patients (7.15%) were retained with a mean age of 53.03 years and a sex ratio of 0.55. Chronic kidney disease was in end-stage in 45.1% (n=23). Cystitis was found in 49.02% (n=25) and gram-negative bacilli were found in 74.50% (n=38), predominantly Escherichia coli (54.90%). Third generation of cephalosporins and fluoroquinolones were frequently prescribed as probabilistic antibiotics. Resistance to beta-lactam antibiotics was 50% for Escherichia coli. Factors influencing severe infection were: advanced age, male gender, urinary lithiasis, multiple antibiotic resistance and non-enterobacterial germs.
Urinary tract infection in chronic kidney disease were frequent and particularly severe.
尿路感染是全球医院感染的主要原因。它是慢性肾脏病进展的一个因素。
确定慢性肾脏病合并尿路感染患者的流行病学、临床、微生物学、治疗及转归情况。
这是一项回顾性描述性研究,于2014年1月至2018年12月对慢性肾脏病合并尿路感染患者进行了为期5年的研究。
共纳入51例患者(7.15%),平均年龄53.03岁,性别比为0.55。45.1%(n = 23)的患者处于慢性肾脏病终末期。膀胱炎占49.02%(n = 25),革兰氏阴性杆菌占74.50%(n = 38),主要为大肠埃希菌(54.90%)。第三代头孢菌素和氟喹诺酮类药物常作为经验性抗生素使用。大肠埃希菌对β-内酰胺类抗生素的耐药率为50%。影响严重感染的因素有:高龄、男性、尿路结石、多重抗生素耐药及非肠杆菌属细菌。
慢性肾脏病患者的尿路感染很常见且尤为严重。